+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 140 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are studying relapsed or refractory multiple myeloma in adults who have already received treatment with lenalidomide and a proteasome inhibitor but whose disease has progressed. The study aims to evaluate the effects of adding SG301 injection to the standard treatment of pomalidomide and dexamethasone. This is a randomized, placebo-controlled, double-blind, multicenter phase III clinical trial. The study has two stages. Stage 1 is to find the right dose of SG301 combined with pomalidomide and dexamethasone. Stage 2 randomly assigns participants to receive either SG301 injection plus pomalidomide and dexamethasone or a placebo plus the same drugs. SG301 and its placebo are given by intravenous infusion weekly for 8 weeks, then every 2 weeks. Pomalidomide capsules are taken orally once daily on days 1 to 21 of each 28-day cycle. Dexamethasone is taken orally or by infusion on days 1, 8, 15, and 22, with dose adjusted for low body weight. Participants continue treatment until their disease progresses, unacceptable side effects occur, or other stopping criteria are met. Researchers will monitor side effects, drug levels in the body, immune response, and treatment effects including progression-free survival and overall survival for up to about 4 years. The study includes regular assessments every 4 weeks initially, then every 8 weeks, with safety followed for about 30 days after treatment ends.

Age: 18Years - 75YearsAll GendersPhase 3
12 locations
P

Actively Recruiting

Researchers are evaluating YL205, a drug given by intravenous infusion, in patients with advanced solid tumors. This multicenter, open-label phase III study in China aims to assess the safety, tolerability, pharmacokinetics how the drug moves through the body, and preliminary effectiveness of YL205. Eligible patients have advanced solid tumors that overexpress Napi2B and include cancers such as ovarian, non-squamous non-small cell lung, renal cell, and endometrial cancer. Participants receive YL205 as a lyophilized powder reconstituted for intravenous infusion at a dose of 160 mg per vial. Treatment is given once every three weeks in cycles, with dose levels adjusted during different study phases dose escalation phase Ia, dose expansion phase Ib, and cohort expansion phase II. The study evaluates at least two dose levels and the recommended phase 2 dose RP2D. Throughout approximately 36 months, participants are closely monitored for dose-limiting toxicities, treatment-emergent adverse events, and serious adverse events. Researchers assess tumor response using RECIST v1.1 criteria, including overall response rate, disease control rate, duration and depth of response, progression-free survival, and overall survival. Pharmacokinetic parameters like AUC, Cmax, and half-life are also measured. Patients undergo tumor sampling and radiological evaluations to track treatment effects and safety.

Age: 18Years +All GendersPhase 1Phase 2
43 locations
E

Actively Recruiting

Researchers are evaluating the LVIVO-TaVec200 product in a dose-escalation and dose-expansion clinical study for adults with relapsed or refractory multiple myeloma who have not responded to at least three prior standard treatments. This early phase 1 study aims to assess the safety, tolerability, anti-tumor effects, and how the product behaves in the body over time. The study is open-label and single-arm, focusing on this specific patient group with measurable disease and a reasonable life expectancy. Participants will receive a single infusion of the LVIVO-TaVec200 product at increasing dose levels. Before the infusion, some participants may receive bridging therapy if needed. The study includes a core period lasting about two years, which covers screening, bridging therapy, treatment, and follow-up phases. Researchers will monitor patients closely throughout this time to determine the recommended dose for future studies. During the study, participants will undergo various assessments, including monitoring for treatment-emergent adverse events, and testing the pharmacokinetics of the product in peripheral blood and bone marrow. These evaluations will continue through the two-year follow-up period after infusion. Participants will be regularly assessed for safety and treatment effects, with ongoing follow-up to track their response and health status throughout the study duration.

Age: 18Years +All GendersEarly Phase 1
5 locations
P

Actively Recruiting

Researchers are evaluating TQB2102 for injection, a new antibody-coupled drug that targets two different parts of the HER2 protein on tumor cells. This study focuses on patients with unresectable locally advanced, recurrent, or metastatic HER2-positive gastroesophageal adenocarcinoma. The trial aims to assess the effectiveness and safety of TQB2102 combined with benmelstobart or penpulimab, with or without chemotherapy, in this patient group. This is a Phase II randomized study sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Participants receive TQB2102 for injection and either benmelstobart or penpulimab, both given intravenously every three weeks. Chemotherapy is taken orally from Day 1 to Day 15 in each 21-day treatment cycle. There are three study groups, each involving different combinations and doses of TQB2102, benmelstobart, penpulimab, and chemotherapy. Treatment continues through multiple cycles as determined by the study protocol. During the study, participants undergo regular assessments including scans and tests to measure tumor response and disease progression. Researchers monitor outcomes like the objective response rate, progression-free survival, duration of response, overall survival, and any adverse events. The study includes follow-up periods to track safety and effectiveness, with an average observation of up to three years. Participants are closely monitored throughout the treatment and follow-up phases for their health and response to therapy.

Age: 18Years - 75YearsAll GendersPhase 2
39 locations
E

Actively Recruiting

Researchers are evaluating the safety and preliminary effectiveness of TQB2930 combined with chemotherapy, with or without bevacizumab, in people who have HER2-abnormally expressed, locally advanced or metastatic colorectal cancer that cannot be removed by surgery. This phase IbII clinical trial aims to better understand how these treatments work together to target cancer cells expressing the HER2 protein. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. and includes adult participants from 18 to 75 years old. Participants are randomly assigned to receive either TQB2930 injection plus chemotherapy and bevacizumab injection or TQB2930 injection plus chemotherapy alone. Chemotherapy drugs include oxaliplatin and capecitabine tablets or irinotecan hydrochloride injection with capecitabine tablets. TQB2930 targets HER2 proteins on tumor cells to reduce their growth, while bevacizumab works by blocking blood vessel formation that feeds tumors. Treatment continues until disease progression or other criteria are met. Throughout the study, participants undergo assessments such as measuring tumor response, monitoring adverse events, and collecting blood samples to analyze drug levels and immune responses. The main outcomes include determining the recommended dose for phase 2, safety monitoring from consent until 28 days after the last dose, and tracking objective response rates for up to 24 months. Secondary outcomes include survival rates, duration of response, and drug behavior in the body. Participants are monitored regularly during treatment and follow-up periods lasting up to two years.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
31 locations
O

Actively Recruiting

Researchers are evaluating the combination of LBL-024 with other drugs for treating patients with advanced biliary tract cancer and hepatocellular carcinoma, both types of advanced solid tumors. This open-label, phase II, multicenter study aims to assess the safety and effectiveness of these combination treatments in this patient population. Two groups of participants, called cohorts, are involved in this study to carefully monitor the treatments tolerability and impact. Participants in Cohort 1 receive LBL-024 combined with gemcitabine and cisplatin, while those in Cohort 2 receive LBL-024 combined with bevacizumab. Both treatment combinations are given through intravenous infusion. Each cohort begins with a 21-day safety observation period to evaluate tolerability. If the treatments are well tolerated, the study continues with additional participants receiving the combination therapies. Throughout the study, participants will be closely monitored with various tests and assessments, including laboratory evaluations and imaging to measure tumor response using RECIST 1.1 criteria. The main measurement is the objective response rate during and after treatment. Researchers will also assess disease control, duration of response, drug concentration levels, and immune response. The study plans to enroll up to 140 participants aged 18 to 75 years, with ongoing safety and efficacy follow-up until 28 days after treatment ends or before new anti-tumor therapy begins.

Age: 18Years - 75YearsAll GendersPhase 2
16 locations
S

Actively Recruiting

Researchers are studying LBL-034 in patients with relapsed or refractory multiple myeloma RRMM and plasma cell leukemia PCL to evaluate its safety, tolerability, pharmacokinetics, immunogenicity, and effectiveness. This open-label, multicenter phase III study includes dose escalation and dose expansion phases to find the recommended dose and dosing schedule. The trial aims to assess treatment response and adverse events in these patients. LBL-034 is given as an intravenous infusion every two weeks. The phase I study involves dose escalation to assess safety and tolerability, including a dose-limiting toxicity observation period lasting four weeks after the first full dose. After determining the recommended phase 2 dose RP2D, the phase II study evaluates efficacy across four patient cohorts, with dosing regimens based on phase I data. Biological samples are collected throughout for additional testing. Participants will be monitored for treatment response, drug levels, immune reaction, and side effects from the time they consent until 30 to 90 days after stopping the drug. Evaluation includes measurement of objective response rate, dose-limiting toxicities, maximum tolerated dose, adverse events, and other key outcomes such as minimal residual disease and soluble BCMA levels. The study will enroll approximately 342 patients and continues until 2027.

Age: 18Years +All GendersPhase 1Phase 2
21 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of TQB6411 for injection in adults with advanced lung cancer. This phase IbII clinical trial aims to find the recommended phase II dosage and assess how well the treatment works in shrinking tumors or controlling the disease. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and focuses on patients aged 18 to 75 years with confirmed lung cancer. Participants will receive TQB6411 injections either every 21 days or every 28 days as treatment cycles. The study involves only one treatment group where all participants receive TQB6411. Each cycle of treatment is followed by assessments to monitor response and safety. The trial includes dose evaluation and efficacy measurement over several months, with extended follow-up for survival and side effects lasting up to three years. During the study, participants will undergo medical evaluations including laboratory tests, imaging scans to measure tumors, and monitoring of adverse events. Blood samples will be taken to study drug levels and antibodies. The main outcomes measured include tumor response rates, disease control, duration of response, progression-free and overall survival. Safety is closely monitored throughout the study. The total participation time may last up to three years, including treatment and follow-up visits.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
38 locations
M

Actively Recruiting

Healthy Volunteer

Researchers are conducting a multi-center clinical study to assess artificial intelligence AI algorithms for measuring heart function and size using echocardiography. The study aims to compare AI measurements with those of physicians at different experience levels, evaluate the accuracy and stability of AI, and explore its use in complex heart conditions like cardiomyopathy, valve disease, and coronary heart disease. The goal is to improve diagnostic consistency and clinical workflows across medical centers. The study involves measuring cardiac chamber size and function in 1600 participants using AI, senior physicians, and intermediate physicians. All measurements are made with Mindray ultrasonic machines. AI and intermediate physician results are completed within one day after data collection, while senior physician results are completed within one month. The study will establish a standardized reference system for AI-assisted echocardiographic measurements and evaluate AIs performance in special cases. Participants will undergo echocardiographic scans with measurements of left and right ventricular size and function, Doppler ultrasound indicators, and valve annulus displacements. Researchers will analyze data to compare AI and physician measurements, assess measurement deviations, and evaluate AIs efficiency in reducing analysis time. The study will run until July 2026, with ongoing data collection and analysis across multiple centers, aiming to promote wider clinical application of AI technology for cardiovascular disease diagnosis.

Age: 18Years - 80YearsAll Genders
37 locations
C

Actively Recruiting

This research aims to compare two oxygen concentration protocolsconstant 5% versus sequential 5%-2%used during embryo culture in assisted reproductive technology. The study focuses on women undergoing blastocyst transplantation to evaluate differences in term live birth rates and offspring health, including potential effects on telomere length, which is linked to aging and health outcomes. The trial is conducted across five centers, including the Clinical Center of Reproductive Medicine at the First Affiliated Hospital of Nanjing Medical University. Participants are randomly assigned to one of two groups one receives embryo culture under a constant 5% oxygen concentration, and the other under a sequential protocol reducing from 5% to 2%. Both groups follow their respective blastocyst culture protocols during in vitro fertilization or intracytoplasmic sperm injection cycles. The study monitors outcomes related to live births and health status of offspring associated with each oxygen protocol. Women enrolled in the trial will be followed for three years, during which live birth rates, clinical pregnancy rates, implantation rates, miscarriage rates, and ectopic pregnancy rates will be recorded. Researchers will also assess offspring health by measuring peripheral blood telomere length. Evaluations include monitoring pregnancy outcomes and any perinatal complications. Data will be statistically analyzed to determine the effects of oxygen concentration protocols on reproductive success and offspring well-being.

Age: 20Years - 40YearsFEMALEPhase Not Applicable
6 locations

1-10 of 140

1